Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: Influence of heteroaryl derivatization on potency and selectivity

Journal of Medicinal Chemistry

Volumn 51, Issue 16, 2008, Pages 5064-5074

  Heim, Ralf ^a   Lucas, Simon ^a   Grombein, Cornelia M ^a   Ries, Christina ^a   Schewe, Katarzyna E ^a   Negri, Matthias ^a   Müller Vieira, Ursula ^b   Birk, Barbara ^b   Hartmann, Rolf W ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b Pharmacelsus CRO   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 (6 METHOXYNAPHTHALEN 2 YL)PYRIDIN 3 YL]ETHANOL; 1 [5 (6 METHOXYNAPHTHALEN 2 YL)PYRIDIN 3 YL]ETHANONE; 3 (1 METHOXYMETHYL) 5 (6 METHOXYNAPHTHALEN 2 YL)PYRIDINE; 3 (6 METHOXY 3 METHYL 3,4 DIHYDRONAPHTHALEN 2 YL)PYRIDINE; 3 (6 METHOXY 3 METHYLNAPHTHALEN 2 YL)PYRIDINE; 3 (6 METHOXYNAPHATHALEN 2 YL) 5 PHENYLPYRIDINE; 3 (6 METHOXYNAPHTHALEN 2 YL) 4 METHYLPYRIDINE; 3 (6 METHOXYNAPHTHALEN 2 YL)PYRIDIN 4 AMINE; 3 (METHOXYMETHYL) 5 (6 METHOXYNAPHTHALEN 2 YL)PYRIDINE; 3 ETHOXY 5 (6 METHOXYNAPHTHALEN 2 YL)PYRIDINE; 3 METHOXY 5 (6 METHOXY 3 METHYLNAPHTHALEN 2 YL)PYRIDINE; 3 METHOXY 5 (6 METHOXYNAPHTHALEN 2 YL)PYRIDINE; 3 METHOXY 5 (6 METHYL 3,4 DIHYDRONAPHTHALEN 2 YL)PYRIDINE; 4 (6 METHOXYNAPHTHALEN 2 YL)ISOQUINOLINE; 4 (METHOXYMETHYL) 3 (6 METHOXYNAPHTHALEN 2 YL)PYRIDINE; 5 (6 METHOXYNAPHTHALEN 2 YL)PYRIDIN 3 OL; 5 (6 METHOXYNAPHTHALEN 2 YL)PYRIDINE 3 CARBOXAMIDE; 5 (6 METHOXYNAPHTHALEN 2 YL)PYRIDINE 3 CARBOXYLIC ACID; 6 (4 METHYLPYRIDIN 3 YL) 2 NAPHTHONITRILE; 6 (PYRIDIN 3 YL) 7,8 DIHYDRONAPHATHALENE 2 CARBONITRILE; [4 (6 METHOXYNAPHTHALEN 2 YL)PYRIDIN 3 YL]METHANOL; [5 (6 METHOXYNAPHTHALEN 2 YL)PYRIDIN 3 YL]ACETIC ACID; [5 (6 METHOXYNAPHTHALEN 2 YL)PYRIDIN 3 YL]METHANOL; ALDOSTERONE SYNTHASE; CYTOCHROME P450 1A2; CYTOCHROME P450 INHIBITOR; FADROZOLE; METHYL 5 (6 METHOXYNAPHTHALEN 2 YL)PYRIDINE 3 CARBOXYLIC ACID; METHYL [5 (6 METHOXYNAPHTHALEN 2 YL)PYRIDIN 3 YL]ACETIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CIRCULATION; CONCENTRATION (PARAMETERS); DRUG POTENCY; DRUG SELECTIVITY; ENZYME INHIBITION; GASTROINTESTINAL TRACT; IC 50; MALE; NONHUMAN; RAT;

ALDOSTERONE SYNTHASE; ANIMALS; CYTOCHROME P-450 CYP1A2; FIBROSIS; HEART FAILURE; HUMANS; MALE; MYOCARDIUM; NAPHTHALENES; RATS; RATS, WISTAR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 50249187635     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800377h     Document Type: Article

References (75)

1. (a) Takeda, Y. Vascular synthesis of aldosterone: role in hypertension. Mol. Cell. Endocrinol. 2004, 217, 75-79.
2. (b) Davies, E.; MacKenzie, S. M. Extra-adrenal production of corticosteroids. Clin. Exp. Pharmacol. Physiol. 2003, 30, 437-445.
3. Kawamoto, T.; Mitsuuchi, Y.; Toda, K.; Yokoyama, Y.; Miyahara, K.; Miura, S.; Ohnishi, T.; Ichikawa, Y.; Nakao, K.; Imura, H.; Ulick, S.; Shizuta, Y. Role of steroid 11β-hydroxylase and steroid 18-hydroxylase in the biosynthesis of glucocorticoids and mineralocorticoids in humans. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 1458-1462.
4. (a) Brilla, C. G. Renin-angiotensin-aldosterone system and myocardial fibrosis. Cardiovasc. Res. 2000, 47, 1-3.
5. (b) Lijnen, P.; Petrov, V. Induction of cardiac fibrosis by aldosterone. J. Mol. Cell. Cardiol. 2000, 32, 865-879.
6. Pitt, B.; Zannad, F.; Remme, W. J.; Cody, R.; Castaigne, A.; Perez, A.; Palensky, J.; Wittes, J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 1999, 341, 709-717.
7. Pitt, B.; Remme, W.; Zannad, F.; Neaton, J.; Martinez, F.; Roniker, B.; Bittman, R.; Hurley, S.; Kleiman, J.; Gatlin, M. Eplerenone, a selective aldosterone blocker in patients with left ventricular dysfunction after myocardial infarction. N. Eng. J. Med. 2003, 348, 1309-1321.
8. Khan, N. U. A.; Movahed, A. The role of aldosterone and aldosterone-receptor antagonists in heart failure. Rev. Cardiovasc. Med. 2004, 5, 71-81.
9. Bell, M. G.; Gernert, D. L.; Grese, T. A.; Belvo, M. D.; Borromeo, P. S.; Kelley, S. A.; Kennedy, J. H.; Kolis, S. P.; Lander, P. A.; Richey, R.; Sharp, V. S.; Stephenson, G. A.; Williams, J. D.; Yu, H.; Zimmerman, K. M.; Steinberg, M. I.; Jadhav, P. K. (S)-N-{3-[1-Cyclopropyl-1-(2,4-difluoro-phenyl)- ethyl]-1H-indol-7-yl}-methanesulfonamide: A potent, nonsteroidal, functional antagonist of the mineralocorticoid receptor. J. Med. Chem. 2007, 50, 6443-6445.
10. (a) Delcayre, C.; Swynghedauw, B. Molecular mechanisms of myocardial remodeling. The role of aldosterone. J. Mol. Cell. Cardiol. 2002, 34, 1577-1584.
11. (b) de Resende, M. M.; Kauser, K.; Mill, J. G. Regulation of cardiac and renal mineralocorticoid receptor expression by captopril following myocardial infarction in rats. Life Sci. 2006, 78, 3066-3073.
12. (a) Wehling, M. Specific, nongenomic actions of steroid hormones. Annu. Rev. Physiol. 1997, 59, 365-393.
13. (b) Lösel, R.; Wehling, M. Nongenomic actions of steroid hormones. Nat. Rev. Mol. Cell. Biol. 2003, 4, 46-55.
14. (c) Chai, W.; Garrelds, I. M.; Arulmani, U.; Schoemaker, R. G.; Lamers, J. M. J.; Danser, A. H. J. Genomic and nongenomic effects of aldosterone in the rat heart: Why is spironolactone cardioprotective? Br. J. Pharmacol. 2005, 145, 664-671.
15. (d) Chai, W.; Garrelds, I. M.; de Vries, R.; Batenburg, W. W.; van Kats, J. P.; Danser, A. H. J. Nongenomic effects of aldosterone in the human heart: Interaction with angiotensin II. Hypertension 2005, 46, 701-706.
16. Ehmer, P. B.; Bureik, M.; Bernhardt, R.; Müller, U.; Hartmann, R. W. Development of a test system for inhibitors of human aldosterone synthase (CYP11B2): Screening in fission yeast and evaluation of selectivity in V79 cells. J. Steroid Biochem. Mol. Biol. 2002, 81, 173-179.
17. Hartmann, R. W.; Müller, U.; Ehmer, P. B. Discovery of selective CYP11B2 (aldosterone synthase) inhibitors for the therapy of congestive heart failure and myocardial fibrosis. Eur. J. Med. Chem. 2003, 38, 363-366.
18. (a) Yamakita, N.; Chiou, S.; Gomez-Sanchez, C. E. Inhibition of aldosterone biosynthesis by 18-ethynyl-deoxycorticosterone. Endocrinology 1991, 129, 2361-2366.
19. (b) Hartmann, R. W. Selective inhibition of steroidogenic P450 enzymes: Current status and future perspectives. Eur. J. Pharm. Sci 1994, 2, 15-16.
20. (a) Viger, A.; Coustal, S.; Perard, S.; Piffeteau, A.; Marquet, A. 18-Substituted progesterone derivatives as inhibitors of aldosterone biosynthesis. J. Steroid Biochem. 1989, 33, 119-124.
21. (b) Delorme, C.; Piffeteau, A.; Viger, A.; Marquet, A. Inhibition of bovine cytochrome P-45011,3 by 18-unsaturated progesterone derivatives. Eur. J. Biochem. 1995, 232, 247-256.
22. 11β by 18-unsaturated progesterone derivatives. Eur. J. Biochem. 1997, 248, 252-260.
23. 11β. Bioorg. Med. Chem. 1998, 6, 1781-1788.
24. Taymans, S. E.; Pack, S.; Pak, E.; Torpy, D. J.; Zhuang, Z.; Stratakis, C. A. Human CYP11B2 (aldosterone synthase) maps to chromosome 8q24.3. J. Clin. Endocrinol. Metab. 1998, 83, 1033-1036.
25. (a) Häusler, A.; Monnet, G.; Borer, C.; Bhatnagar, A. S. Evidence that corticosterone is not an obligatory intermediate in aldosterone biosynthesis in the rat adrenal. J. Steroid Biochem. 1989, 34, 567-570.
26. (b) Demers, L. M.; Melby, J. C.; Wilson, T. E.; Lipton, A.; Harvey, H. A.; Santen, R. J. The effects of CGS 16949A, an aromatase inhibitor on adrenal mineralocorticoid biosynthesis. J. Clin. Endocrinol. Metab. 1990, 70, 1162-1166.
27. Fiebeler, A.; Nussberger, J.; Shagdarsuren, E.; Rong, S.; Hilfenhaus, G.; Al-Saadi, N.; Dechend, R.; Wellner, M.; Meiners, S.; Maser-Gluth, C.; Jeng, A. Y.; Webb, R. L.; Luft, F. C.; Muller, D. N. Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation 2005, 111, 3087-3094.
28. (a) Ksander, G.; Hu, Q.-Y. Fused imidazole derivatives for the treatment of disorders mediated by aldosterone synthase and/or 11-beta-hydroxylase and/or aromatase. PCT Int. Appl. WO2008027284, 2008.
29. (b) Papillon J.; Ksander, G. M.; Hu, Q.-Y. Preparation of tetrahydroimidazo[1,5-a]pyrazine derivatives as aldosterone synthase and/or 11β-hydroxylase inhibitors. PCT Int. Appl. WO2007139992, 2007.
30. (c) Adams, C.; Papillon, J.; Ksander, G. M. Preparation of imidazole derivatives as aldosterone synthase inhibitors. PCT Int. Appl. WO2007117982, 2007.
31. (d) Ksander, G. M.; Meredith, E.; Monovich, L. G.; Papillon, J.; Firooznia, F.; Hu, Q.-Y. Preparation of condensed imidazole derivatives for the inhibition of aldosterone synthase and aromatase. PCT Int. Appl. WO2007024945, 2007.
32. (e) Firooznia, F. Preparation of imidazo[1,5a]pyridine derivatives for treatment of aldosterone mediated diseases. PCT Int. Appl. WO2004046145, 2004.
33. (f) McKenna, J. Preparation of imidazopyrazines and imidazodiazepines as agents for the treatment of aldosterone mediated conditions. PCT Int. Appl. WO200401491, 2004.
34. (a) Herold, P.; Mah, R.; Tschinke, V.; Stojanovic, A.; Marti, C.; Jelakovic, S.; Stutz, S. Preparation of imidazo compounds as aldosterone synthase inhibitors. PCT Int. Appl. WO2007116099, 2007.
35. (b) Herold, P.; Mah, R.; Tschinke, V.; Stojanovic, A.; Marti, C.; Jelakovic, S.; Bennacer, B.; Stutz, S. Preparation of spiro-imidazo derivatives as aldosterone synthase inhibitors. PCT Int. Appl. WO2007116098, 2007.
36. (c) Herold, P.; Mah, R.; Tschinke, V.; Stojanovic, A.; Marti, C.; Stutz, S. Preparation of imidazo compounds as aldosterone synthase inhibitors. PCT Int. Appl. WO2007116097, 2007.
37. (d) Herold, P.; Mah, R.; Tschinke, V.; Quirmbach, M.; Marti, C.; Stojanovic, A.; Stutz, S. Preparation of fused imidazoles as aldosterone synthase inhibitors. PCT Int. Appl. WO2007065942, 2007.
38. (e) Herold, P.; Mah, R.; Tschinke, V.; Stojanovic, A.; Marti, C.; Jotterand, N.; Schumacher, C.; Quirmbach, M. Preparation of heterocyclic spiro-compounds as aldosterone synthase inhibitors. PCT Int. Appl. WO2006128853, 2006.
39. (f) Herold, P.; Mah, R.; Tschinke, V.; Stojanovic, A.; Marti, C.; Jotterand, N.; Schumacher, C.; Quirmbach, M. Preparation of heterocyclic spiro-compounds as aldosterone synthase inhibitors. PCT Int. Appl. WO2006128852, 2006.
40. (g) Herold, P.; Mah, R.; Tschinke, V.; Stojanovic, A.; Marti, C.; Jotterand, N.; Schumacher, C.; Quirmbach, M. Preparation of fused imidazoles as aldosterone synthase inhibitors. PCT Int. Appl. WO2006128851, 2006.
41. (h) Herold, P.; Mah, R.; Tschinke, V.; Schumacher, C.; Marti, C.; Quirmbach, M. Preparation of fused heterocycles as aldosterone synthase inhibitors. PCT Int. Appl. WO2006005726, 2006.
42. (i) Herold, P.; Mah, R.; Tschinke, V.; Schumacher, C.; Quirmbach, M. Preparation of Imidazopyridines and related analogs as aldosterone synthase inhibitors. PCT Int. Appl. WO2005118557, 2005.
43. (j) Herold, P.; Mah, R.; Tschinke, V.; Schumacher, C.; Quirmbach, M. Preparation of tetrahydro-imidazo [1,5-a]pyridin derivatives as aldosterone synthase inhibitors. PCT Int. Appl. WO2005118581, 2005.
44. (k) Herold, P.; Mah, R.; Tschinke, V.; Schumacher, C.; Behnke, D.; Quirmbach, M. Preparation of nitrogen-containing heterobicyclic compounds as aldosterone synthase inhibitors. PCT Int. Appl. WO2005118541, 2005.
45. Ulmschneider, S.; Müller-Vieira, U.; Mitrenga, M.; Hartmann, R. W.; Oberwinkler-Marchais, S.; Klein, C. D.; Bureik, M.; Bernhardt, R.; Antes, I.; Lengauer, T. Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: Potent inhibitors of aldosterone synthase. J. Med. Chem. 2005, 48, 1796-1805.
46. Ulmschneider, S.; Müller-Vieira, U.; Klein, C. D.; Antes, I.; Lengauer, T.; Hartmann, R. W. Synthesis and evaluation of (pyridylmethylene) tetrahydronaphthalenes/-indanes and structurally modified derivatives: Potent and selective inhibitors of aldosterone synthase. J. Med. Chem. 2005, 48, 1563-1575.
47. Voets, M.; Antes, I.; Scherer, C.; Müller-Vieira, U.; Biemel, K.; Barassin, C.; Oberwinkler-Marchais, S.; Hartmann, R. W. Heteroaryl substituted naphthalenes and structurally modified derivatives: Selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis. J. Med. Chem. 2005, 48, 6632-6642.
48. Voets, M.; Antes, I.; Scherer, C.; Müller-Vieira, U.; Biemel, K.; Oberwinkler-Marchais, S.; Hartmann, R. W. Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: Potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis. J. Med. Chem. 2006, 49, 2222-2231.
49. Ulmschneider, S.; Negri, M.; Voets, M.; Hartmann, R. W. Development and evaluation of a pharmacophore model for inhibitors of aldosterone synthase (CYP11B2). Bioorg. Med. Chem. Lett. 2006, 16, 25-30.
50. (a) Eaton, D. L.; Gallagher, E. P.; Bammler, T. K.; Kunze, K. L. Role of cytochrome P4501A2 in chemical carcinogenesis: Implications for human variability in expression and enzyme activity. Pharmacogenetics 1995, 5, 259-274.
51. (b) Guengerich, F.; Parikh, A.; Turesky, R. J.; Josephy, P. D. Interindividual differences in the metabolism of environmental toxicants: Cytochrome P450 1A2 as a prototype. Mutat. Res. 1999, 428, 115-124.
52. Miyaura, N.; Suzuki, A. Palladium-catalyzed cross-coupling reactions of organoboron compounds. Chem. Rev. 1995, 95, 2457-2483.
53. Appukkuttan, P.; Orts, A. B.; Chandran, R. P.; Goeman, J. L.; van der Eycken, J.; Dehaen, W.; van der Eycken, E. Generation of a small library of highly electron-rich 2-(hetero)aryl-substituted phenethylamines by the Suzuki-Miyaura reaction: A short synthesis of an apogalanthamine analogue. Eur. J. Org. Chem. 2004, 3277-3285.
54. Bengtson, A.; Hallberg, A.; Larhed, M. Fast synthesis of aryl triflates with controlled microwave heating. Org. Lett. 2002, 4, 1231-1233.
55. Kertesz, D. J.; Martin, M.; Palmer, W. S. Process for preparing pyridazinone compounds. PCT Int. Appl. WO2005100323, 2005.
56. Lézé, M.-P.; Le Borgne, M.; Pinson, P.; Palusczak, A.; Duflos, M.; Le Baut, G.; Hartmann, R. W. Synthesis and biological evaluation of 5-[(aryl)(1H-imidazol-1-yl)methyl]-1H-indoles: Potent and selective aromatase inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 1134-1137.
57. Carreño, M. C.; Garcia-Cerrada, S.; Urbano, A. From central to helical chirality: Synthesis of P and M enantiomers of [5]helicenequinones and bisquinones from (SS)-2-(p-tolylsulfinyl)-1,4-benzoquinone. Chem. Eur. J. 2003, 9, 4118-4131.
58. Heyer, D.; Fang, J.; Navas, F., III; Katamreddy, S. R.; Peckham, J. P.; Turnbull, P. S.; Miller, A. B.; Akwabi-Ameyaw, A. Chemical compounds. PCT Int. Appl. WO2006002185, 2006.
59. Fitzgerald, D. H.; Muirhead, K. M.; Botting, N. P. A comparative study on the inhibition of human and bacterial kynureninase by novel bicyclic kynurenine analogues. Bioorg. Med. Chem. 2001, 9, 983-989.
60. (a) Leadbeater, N. E.; Marco, M. Ligand-free palladium catalysis of the Suzuki reaction in water using microwave heating. Org. Lett. 2002, 4, 2973-2976.
61. (b) Liu, L.; Zhang, Y.; Xin, B. Synthesis of biaryls and polyaryls by ligand-free Suzuki reaction in aqueous phase. J. Org. Chem. 2006, 71, 3994-3997.
62. Li, D.; Zhao, B.; Sim, S.; Li, T.; Liu, A.; Liu, L. F.; LaVoie, E. J. 8,9-Methylenedioxybenzo[i]phenanthridines: Topoisomerase I-targeting activity and cytotoxicity. Bioorg. Med. Chem. 2003, 11, 3795-3805.
63. (a) Denner, K.; Bernhardt, R. Inhibition studies of steroid conversions mediated by human CYP11B1 and CYP11B2 expressed in cell cultures. In Oxygen Homeostasis and Its Dynamics, 1st ed.; Ishimura, Y., Shimada, H., Suematsu, M. Eds.; Springer-Verlag: Tokyo, Berlin, Heidelberg, New York, 1998; pp 231-236.
64. (b) Denner, K.; Doehmer, J.; Bernhardt, R. Cloning of CYP11B1 and CYP11B2 from normal human adrenal and their functional expression in COS-7 and V79 Chinese hamster cells. Endocr. Res. 1995, 21, 443-448.
65. (c) Böttner, B.; Denner, K.; Bernhardt, R. Conferring aldosterone synthesis to human CYP11B1 by replacing key amino acid residues with CYP11B2-specific ones. Eur. J. Biochem. 1998, 252, 458-466.
66. 17,20-lyase (P450c17) by coexpression of P450c17 with NADPH-cytochrome-P450-reductase in Escherichia coli. J. Steroid Biochem. Mol. Biol. 2000, 75, 57-63.
67. (b) Hutschenreuter, T. U.; Ehmer, P. B.; Hartmann, R. W. Synthesis of hydroxy derivatives of highly potent nonsteroidal CYP17 inhibitors as potential metabolites and evaluation of their activity by a noncellular assay using recombinant enzyme. J. Enzyme lnhib. Med. Chem. 2004, 19, 17-32.
68. Thompson, E. A.; Siiteri, P. K. Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione. J. Biol. Chem. 1974, 249, 5364-5372.
69. Hartmann, R. W.; Batzl, C. Aromatase inhibitors. Synthesis and evaluation of mammary tumor inhibiting activity of 3-alkylated 3-(4-aminophenyl) piperidine-2,6-diones. J. Med. Chem. 1986, 29, 1362-1369.
70. PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 7696-7700.
71. Sesardic, D.; Boobis, A. R.; Murray, B. P.; Murray, S.; Segura, J.; de la Torre, R.; Davies, D. S. Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. Br. J. Clin. Pharmacol. 1990, 29, 651-663.
72. (a) Chohan, K. K.; Paine, S. W.; Mistry, J.; Barton, P.; Davis, A. M. A rapid computational filter for cytochrome P450 1A2 inhibition potential of compound libraries. J. Med. Chem. 2005, 48, 5154-5161.
73. (b) Korhonen, L. E.; Rahnasto, M.; Mähönen, N. J.; Wittekindt, C.; Poso, A.; Juvonen, R. O.; Raunio, H. Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J. Med. Chem. 2005, 48, 3808-3815.
74. Dennington, I.; Roy; Keith, T.; Millam, J. ; Eppinnett, K.; Hovell, W. L.; Gilliland, R. GaussView, Version 3.0; Semichem Inc.: Shawnee Mission, KS, 2003.
75. Petti, M. A.; Shepodd, T. J.; Barrans, R. E. ; Dougherty, D. A. "Hydrophobic" binding of water-soluble guests by high-symmetry, chiral hosts. An electron-rich receptor site with a general affinity for quaternary ammonium compounds and electron-deficient π systems. J. Am. Chem. Soc. 1988, 110, 6825-6840.